Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-5218 in Type 2 Diabetes Inadequately Controlled with Metformin
NCT07229534Phase 4Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of DA5221-B2, dapagliflozin, metformin in type 2 diabetes mellitus (T2DM), sponsored by Dong-A ST. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
DA5221-B2dapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07229534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229534.